Stock listing
NASDAQ:EIKN Eikon Therapeutics, Inc. Stock
Home listing (NASDAQ) of Eikon Therapeutics, Inc.
Follow Eikon Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:EIKN
$4.74 USD -0.43 (-8.3%)
Close on Nov 20, 2026
- Day range
- $4.74 – $5.19 USDNov 20, 2026
- Volume
- 691,438 sharesNov 20, 2026
- Market cap
- $256.8M USDAt the close on Nov 20, 2026 · price × 54.19M shares outstanding
- Traded on an average day
- $4.45M USDMedian day 532,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EIKN · Home | $4.74 USD | -0.43 (-8.3%) | 691,438 | $4.85 | $5.19 | $4.74 | $5.17 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EIKN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.74 | -0.43 | -8.3% | $4.85 | $5.19 | $4.74 | 691,438 | |
| $5.17 | +0.02 | +0.4% | $5.11 | $5.38 | $5.02 | 392,298 | |
| $5.15 | -0.235 | -4.4% | $5.39 | $5.39 | $4.95 | 477,037 | |
| $5.385 | -0.595 | -9.9% | $5.97 | $6.19 | $5.27 | 496,234 | |
| $5.98 | -0.06 | -1.0% | $6.06 | $6.10 | $5.585 | 294,007 | |
| $6.04 | -0.63 | -9.4% | $6.68 | $6.725 | $5.84 | 735,487 | |
| $6.67 | +0.54 | +8.8% | $6.08 | $6.81 | $6.08 | 439,191 | |
| $6.13 | +0.26 | +4.4% | $5.87 | $6.33 | $5.73 | 424,891 | |
| $5.87 | -0.03 | -0.5% | $6.03 | $6.04 | $5.62 | 722,194 | |
| $5.90 | +0.06 | +1.0% | $5.79 | $6.065 | $5.63 | 401,467 | |
| $5.84 | -0.55 | -8.6% | $6.39 | $6.43 | $5.75 | 787,738 | |
| $6.39 | +0.84 | +15.1% | $5.69 | $6.42 | $5.36 | 658,571 | |
| $5.55 | -0.13 | -2.3% | $5.68 | $6.018 | $5.35 | 556,047 | |
| $5.68 | +0.37 | +7.0% | $5.35 | $5.755 | $5.21 | 409,342 | |
| $5.31 | -0.04 | -0.7% | $5.27 | $5.40 | $5.01 | 552,600 | |
| $5.35 | -0.19 | -3.4% | $5.69 | $5.83 | $5.28 | 574,800 | |
| $5.54 | -0.01 | -0.2% | $5.49 | $5.71 | $5.32 | 660,600 | |
| $5.55 | +0.01 | +0.2% | $5.56 | $5.99 | $5.51 | 697,200 | |
| $5.54 | -1.72 | -23.7% | $7.20 | $7.44 | $5.44 | 965,600 | |
| $7.26 | -0.98 | -11.9% | $8.07 | $8.07 | $7.20 | 318,400 | |
| $8.24 | +0.24 | +3.0% | $7.98 | $8.29 | $7.93 | 348,500 | |
| $8.00 | -0.18 | -2.2% | $8.12 | $8.40 | $7.97 | 240,700 | |
| $8.18 | +0.48 | +6.2% | $7.75 | $8.48 | $7.67 | 336,400 | |
| $7.70 | +0.28 | +3.8% | $7.45 | $8.21 | $7.13 | 700,900 | |
| $7.42 | -0.12 | -1.6% | $7.73 | $7.76 | $7.19 | 482,800 | |
| $7.54 | +0.53 | +7.6% | $7.01 | $7.69 | $7.01 | 654,400 | |
| $7.01 | +0.29 | +4.3% | $6.69 | $7.07 | $6.45 | 595,500 | |
| $6.72 | -0.54 | -7.4% | $7.19 | $7.30 | $6.71 | 406,700 | |
| $7.26 | -0.21 | -2.8% | $7.45 | $7.60 | $7.16 | 236,200 | |
| $7.47 | -0.03 | -0.4% | $7.48 | $7.82 | $7.25 | 288,700 | |
| $7.50 | -0.04 | -0.5% | $7.48 | $7.74 | $7.19 | 847,100 | |
| $7.54 | +0.03 | +0.4% | $7.32 | $7.63 | $7.11 | 920,200 | |
| $7.51 | -0.03 | -0.4% | $7.67 | $7.84 | $7.43 | 610,800 | |
| $7.54 | +0.21 | +2.9% | $7.42 | $7.66 | $7.02 | 485,300 | |
| $7.33 | -0.08 | -1.1% | $7.55 | $7.55 | $7.07 | 420,400 | |
| $7.41 | -0.63 | -7.8% | $8.00 | $8.09 | $7.40 | 624,600 | |
| $8.04 | +0.13 | +1.6% | $7.95 | $8.16 | $7.71 | 585,800 | |
| $7.91 | 0.00 | 0.0% | $7.88 | $8.10 | $7.80 | 334,800 | |
| $7.91 | -0.01 | -0.1% | $7.81 | $8.00 | $7.55 | 435,000 | |
| $7.92 | -0.37 | -4.5% | $8.45 | $8.47 | $7.87 | 377,100 | |
| $8.29 | +0.16 | +2.0% | $8.14 | $8.40 | $7.72 | 710,000 | |
| $8.13 | -0.85 | -9.5% | $8.94 | $8.94 | $7.96 | 727,300 | |
| $8.98 | +0.15 | +1.7% | $8.97 | $9.33 | $8.75 | 430,700 | |
| $8.83 | -0.12 | -1.3% | $9.06 | $9.16 | $8.65 | 463,900 | |
| $8.95 | +0.35 | +4.1% | $8.70 | $9.09 | $8.65 | 2,242,400 | |
| $8.60 | +0.09 | +1.1% | $8.65 | $9.33 | $8.57 | 640,200 | |
| $8.51 | -0.98 | -10.3% | $9.47 | $9.64 | $8.39 | 989,400 | |
| $9.49 | +0.13 | +1.4% | $9.33 | $10.24 | $9.08 | 843,400 | |
| $9.36 | +0.42 | +4.7% | $8.95 | $9.44 | $8.93 | 713,100 | |
| $8.94 | -0.27 | -2.9% | $9.28 | $9.56 | $8.79 | 1,010,200 | |
| $9.21 | -1.52 | -14.2% | $10.65 | $10.68 | $9.17 | 665,100 | |
| $10.73 | +0.02 | +0.2% | $11.01 | $11.47 | $10.63 | 752,400 | |
| $10.71 | -0.15 | -1.4% | $10.81 | $11.03 | $10.61 | 462,300 | |
| $10.86 | -0.10 | -0.9% | $10.81 | $11.05 | $10.62 | 238,700 | |
| $10.96 | -0.42 | -3.7% | $11.45 | $11.66 | $10.91 | 384,300 | |
| $11.38 | +0.50 | +4.6% | $10.91 | $11.67 | $10.65 | 552,800 | |
| $10.88 | +0.42 | +4.0% | $10.31 | $10.94 | $10.10 | 333,500 | |
| $10.46 | -0.52 | -4.7% | $10.89 | $10.91 | $10.45 | 290,700 | |
| $10.98 | -0.54 | -4.7% | $11.41 | $11.45 | $10.90 | 239,600 | |
| $11.52 | -0.46 | -3.8% | $11.97 | $12.24 | $11.46 | 261,700 | |
| $11.98 | -0.57 | -4.5% | $12.56 | $13.00 | $11.90 | 324,100 | |
| $12.55 | +1.39 | +12.5% | $11.26 | $12.82 | $11.24 | 567,204 | |
| $11.16 | -0.23 | -2.0% | $11.59 | $11.92 | $10.94 | 398,364 | |
| $11.39 | +0.64 | +6.0% | $10.87 | $12.11 | $10.75 | 532,800 | |
| $10.75 | -1.26 | -10.5% | $11.90 | $12.04 | $10.40 | 559,700 |
- Ticker
- NASDAQ:EIKN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
Latest deck · November 2026
Corporate Update (November 2026)
Corporate update · 56 slides
Latest news
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
Nov 17, 2026
Closed $5.15 (-4.4%) on Nov 17, 2026
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Nov 12, 2026
Closed $6.04 (-9.4%) on Nov 12, 2026
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
Nov 2, 2026
Closed $5.68 (+7.0%) on Nov 2, 2026
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Oct 26, 2026
Closed $5.54 (-23.7%) on Oct 26, 2026
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Oct 23, 2026
Closed $7.26 (-11.9%) on Oct 23, 2026
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Oct 18, 2026
Closed $7.70 (+3.8%) on Oct 19, 2026
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Oct 15, 2026
Closed $7.54 (+7.6%) on Oct 15, 2026
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Sep 3, 2026
Closed $10.96 (-3.7%) on Sep 3, 2026
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Aug 26, 2026
Closed $11.98 (-4.5%) on Aug 26, 2026
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Aug 18, 2026
Closed $12.01 (+3.1%) on Aug 19, 2026
Eikon Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 22 in all · newest Nov 17, 2026 · oldest 2026
- Decks
- 4 decks · latest November 2026
Where Eikon Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EIKN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:EIKN | BOATS | United States | USD |
| BX Swiss:EIKN | BX Swiss | Switzerland | CHF |
Valuation
Price/book 0.7× against a median of 2.0×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $44.67M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.7×
- Beta vs S&P 500
- 1.91
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.5M | US$243.4M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.4M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | n/a |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Median of the others | US$258.5M | US$128.0M | 21.8× | 2.0× | −196.0% | 0.1× | 1.48 |
Forecasts
4 strong buy · 2 buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 24.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.45 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Roger Perlmutter | Chief Executive Officer |
| Alfred Bowie | Chief Financial Officer |
| Mike Klobuchar | Chief Operating Officer |
| Ben Thorner | Chief Business Officer and General Counsel |
| Ching-Pin Chang | Executive Vice President and Chief Scientific Officer |
| Barbara Howes | Chief People Officer |
| Roy Baynes | Chief Medical Officer |
| Russ Berman | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Alfred Bowie | Chief Financial Officer |
| Barbara Howes | Chief People Officer |
| Ma. Fatima D. Francisco | Director |
| Roger Perlmutter | Chief Executive Officer |
| Roy Baynes | Chief Medical Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −9.4% |
| Q2 2026 | Aug 13, 2026 · After close | +7.0% |
| Q1 2026 | May 11, 2026 · After close | +15.9% |
| Q4 2025 | Mar 30, 2026 | +7.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 56 slides | November 2026 |
| Corporate Update (August 2026) | Corporate update | 33 slides | Aug 14, 2026 |
| Corporate Update (June 2026) | Corporate update | 49 slides | Jun 1, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | May 11, 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$381M · US$18 a share · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), BofA Securities (co-lead), Cantor (co-lead), Mizuho (co-lead) | Feb 5, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Feb 4, 2026.
- Price
- US$18.00 a share
- Shares offered
- 21,177,600 shares of common stock
- Offering size
- US$381.2 million
- Underwriters' option
- Up to 3,176,640 more shares
- Listing
- EIKN on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, Mizuho · In the order on the cover
- Shares delivered
- On or about Feb 6, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 9, 2025 |
| Filed publicly | Jan 9, 2026 |
| Amended once | Jan 28, 2026 |
| Shares registered with an exchange | Jan 28, 2026 |
| Declared effective by the SEC | Jan 30, 2026 |
| Final prospectus, with the price | Feb 5, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 5, 2026 |
| S-1MEF · Registration of more shares for the same offering | Feb 4, 2026 |
| CERT · Exchange's certificate of listing | Feb 4, 2026 |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 28, 2026 |
| S-1/A · Registration statement, amended | Jan 28, 2026 |
| S-1 · Registration statement | Jan 9, 2026 |
| DRS/A · Draft registration statement, amended | Dec 12, 2025 |
| DRS/A · Draft registration statement, amended | Sep 26, 2025 |
| DRS/A · Draft registration statement, amended | Jul 1, 2025 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | May 9, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of revenue | 24.2M | ||
| Gross profit | -24.2M | ||
| Research and development | 250.3M | 204.5M | 207.3M |
| Selling, general and administrative | 88.6M | 55.8M | 58.5M |
| Operating income | -338.9M | -260.3M | -265.7M |
| Depreciation and amortization | 24.2M | 25.4M | 17.7M |
| EBITDA | -314.8M | -235.0M | -248.0M |
| Interest expense | 837.0K | 31.0K | 39.0K |
| Income before tax | -324.2M | -243.8M | -242.0M |
| Net income | -324.2M | -243.8M | -242.0M |
| Earnings per share, basic | -5.99 | -4.52 | -4.48 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 104.9M | 129.2M | 112.8M |
| Short-term investments | 231.1M | 90.9M | 317.6M |
| Current assets | 348.9M | 227.9M | 436.4M |
| Total assets | 594.7M | 491.2M | 525.7M |
| Accounts payable | 681.0K | 17.6M | 2.19M |
| Current liabilities | 55.0M | 56.4M | 31.4M |
| Total debt | 257.3M | ||
| Total liabilities | 1.47B | 1.06B | 867.1M |
| Shareholders' equity | -879.0M | -571.9M | -341.4M |
| Shares outstanding | 54.1M | 54.0M | 54.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -188.5M | -134.8M | -190.8M |
| Capital spending | -46.7M | -84.8M | -28.5M |
| Free cash flow | -235.3M | -219.6M | -219.4M |
| Cash from investing | -181.3M | ||
| Cash from financing | 352.1M | 244.0K | 105.8M |
| Change in cash | -17.8M | 16.8M | 51.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
All 69 filings
Cap table
Built by 6ix from Eikon Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 54,186,095
- Fully diluted
- 54,186,095
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 54,186,095 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 54,186,095 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert L. Huffines Other companies: Becton, Dickinson and Company (Director · Since at least Dec 1, 2025); Insulet Corporation (Director · Since at least Oct 23, 2025); Walgreens Boots Alliance Inc (Director · Since at least Jan 25, 2024); Solid Biosciences Inc. (Director · Jun 7, 2022 – Dec 13, 2022 · Past) | Director · Since at least Feb 4, 2026 |
| Leon Chen Other companies: Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 6, 2021 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past) | Director · Since at least Feb 4, 2026 |
| Roger Perlmutter Other companies: NGM Biopharmaceuticals Inc (Director · May 18, 2022 – Apr 5, 2024 · Past) | See remarks, Director · Since at least Feb 4, 2026 |
| Alfred Bowie | Chief Financial Officer · Since at least Nov 2, 2026 |
| Alfred Lloyd Bowie Jr | Chief Financial Officer · Since at least Feb 4, 2026 |
| Barbara Howes | Chief People Officer · Since at least Nov 5, 2026 |
| Benjamin Bruno Thorner | See Remarks · Since at least Feb 4, 2026 |
| Ben Thorner | Chief Business Officer and General Counsel · Since at least Nov 4, 2026 |
| Ching-Pin Chang | Executive Vice President and Chief Scientific Officer · Since at least Sep 3, 2026 |
| Ma. Fatima D. Francisco | Director · Since at least Jun 8, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Mike Klobuchar | Chief Operating Officer · Since at least Nov 4, 2026 |
| Roy Baynes | Chief Medical Officer · Since at least Nov 2, 2026 |
| Russ Berman | Chief Technology Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Eikon Therapeutics, Inc.